Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22163776 | 0.80 | GSK3B (0.57) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1305020 | 0.80 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL241664 | 0.80 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL3840781 | 0.79 | GSK3B (0.68) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL2626830 | 0.79 | HDAC1 (0.61) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL3469826 | 0.78 | GSK3B (0.71) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL9909660 | 0.78 | PTPN1 (0.41) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1146715 | 0.78 | TSHR (0.60) | CES2CES1CA1CA2 | |
| SCHEMBL70930 | 0.78 | GSK3B (1.00) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL11571 | 0.78 | NPC1 (0.64) | CES2CES1CA1CA2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4293024-B1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706774-A2 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2025-11-06 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | ASTELLAS PHARMA INC. (JP) | 2025-08-12 | — | — | US | disclosed |
| CN-120058445-A | Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method | 华东师范大学 | 2025-05-30 | — | — | CN | disclosed |
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2025-02-27 | — | — | US | disclosed |
| WO-2024232599-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE INHIBITING BET PROTEIN AND COMPOSITION FOR TREATMENT OF CANCER, USING SAME | 주식회사 베노바이오 | 2024-11-14 | — | — | WO | disclosed |
| CN-107629022-B | Antibacterial synergist and preparation method and application thereof | 上海医药工业研究院 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1741693-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | Nagoya Industrial Science Research Institute (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-6951876-B2 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6603008-B1 | Inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1104760-B1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PFIZER PROD INC (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | ADH1C, ADH1A, ADH5 | GSK3B 2227/4885HDAC1 3290/4885HDAC8 4086/4885 |
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | KRAS, NRAS, HRAS | GSK3B 2076/4885HDAC1 1842/4885HDAC8 2527/4885 |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | GSK3B 2076/4885HDAC1 1842/4885HDAC8 2527/4885 |
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | GSK3B 805/4885HDAC1 3302/4885HDAC8 3483/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | GSK3B 750/4885HDAC1 1363/4885HDAC8 1357/4885 |
| US-20030144280-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | PTGS1, PTGS2, SULT2A1 | GSK3B 4567/4885HDAC1 167/4885HDAC8 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.